Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 16Active not recruiting 5Not yet recruiting 2Completed 2Terminated 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 10Glioblastoma 10Breast Neoplasms 10Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Lung Neoplasms 6Colorectal Neoplasms 6Carcinoma, Hepatocellular 6Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Pancreatic Neoplasms 5Hematologic Neoplasms 5Ovarian Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Glioma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Melanoma 3Head and Neck Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Solid Tumors 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

TAK-243 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Anemia, Refractory, with Excess of Blasts × 90 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡